Patrick Michael Murphy
Known title: CLO & EVP RA/QA MrktAcs & GovCIK: 0001692785
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
Transaction History
| IRTC | ▼ Sell | Open Market | 7,093 | $884K | 8/10/2026 | View on chart |
| IRTC | ▲ Buy | Grant | 13,589 | $0 | 8/7/2026 | View on chart |
| IRTC | ▼ Sell | Open Market | 2,028 | $260K | 3/2/2026 | View on chart |
| IRTC | ▼ Sell | Open Market | 1,190 | $153K | 3/2/2026 | View on chart |
| IRTC | ▼ Sell | Open Market | 1,139 | $146K | 3/2/2026 | View on chart |
| IRTC | ▲ Buy | Grant | 7,024 | $0 | 2/25/2026 | View on chart |
| IRTC | ▼ Sell | Open Market | 7,805 | $1.1M | 2/25/2026 | View on chart |
| IRTC | ▲ Buy | Grant | 15,060 | $0 | 2/24/2026 | View on chart |
| IRTC | ▼ Sell | Open Market | 2,478 | $458K | 12/2/2025 | View on chart |
| IRTC | ▼ Sell | Open Market | 3,075 | $334K | 3/3/2025 | View on chart |
| IRTC | ▼ Sell | Open Market | 3,817 | $428K | 2/26/2025 | View on chart |
| IRTC | ▲ Buy | Grant | 8,976 | $0 | 2/26/2025 | View on chart |
| IRTC | ▼ Sell | Open Market | 12,513 | $1.4M | 2/26/2025 | View on chart |
| IRTC | ▲ Buy | Grant | 23,558 | $0 | 2/25/2025 | View on chart |
| IRTC | ▲ Buy | Grant | 7,303 | $0 | 2/25/2025 | View on chart |
| IRTC | ▼ Sell | Open Market | 2,492 | $214K | 12/2/2024 | View on chart |
| IRTC | ▼ Sell | Open Market | 1,525 | $169K | 3/4/2024 | View on chart |
| IRTC | ▼ Sell | Open Market | 7,615 | $929K | 2/29/2024 | View on chart |
| IRTC | ▲ Buy | Grant | 8,593 | $0 | 2/28/2024 | View on chart |
| IRTC | ▲ Buy | Grant | 17,233 | $0 | 2/27/2024 | View on chart |
| IRTC | ▼ Sell | Open Market | 1,686 | $150K | 12/5/2023 | View on chart |
| IRTC | ▼ Sell | Open Market | 571 | $67K | 3/3/2023 | View on chart |
| IRTC | ▲ Buy | Grant | 9,282 | $0 | 2/27/2023 | View on chart |
| IRTC | ▼ Sell | Open Market | 1,704 | $182K | 12/2/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 975 | $528K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 12 | $7K | 9/9/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 500 | $259K | 8/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
iRhythm Reports Data Breach and Completes VitalConnect Acquisition
iRhythm disclosed unauthorized access to patient data, a significant security event for a healthcare company. The firm also completed the acquisition of VitalConnect to expand its cardiac monitoring platform across various care settings. Analyst views remain mixed, with Wells Fargo lowering its price target to $150 while Needham raised its target to $194.
iRhythm Reports Data Breach and Completes VitalConnect Acquisition. iRhythm disclosed unauthorized access to patient data, a significant security event for a healthcare company. The firm also completed the acquisition of VitalConnect to expand its cardiac monitoring platform across various care settings. Analyst views remain mixed, with Wells Fargo lowering its price target to $150 while Needham raised its target to $194.